EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Similar Posts
eyecro COO Gives Talk at ARVO
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
Triumph for MiDROPS® in Clinical Trials
We are proud to announce a significant breakthrough in ophthalmic care: our innovative MiDROPS® technology has been validated for safety and efficacy in its first clinical application. Data from the technology’s first clinical application is being presented at the 96th meeting of the Association for Research in Vision and Ophthalmology in Seattle, WA. Read the…
eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference
The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…
MiDROPS® Achieves Clinical Safety and Efficacy Milestone
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™
EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…
Bio Matters: Family influences led eyecro’s executive into scientific research
Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…
